Targeted Endocrine Therapy: Design, Synthesis, and Proof-of-Principle of 17β-Hydroxysteroid Dehydrogenase Type 2 Inhibitors in Bone Fracture Healing
Authors:
- Ahmed S. AbdelsamieAAAhmed S. Abdelsamie
- Steven HerathSHSteven Herath
- Yannik BiskupekYBYannik Biskupek
- Mohamed SalahMSMohamed Salah
- Claudia ScheuerCSClaudia Scheuer
- Sandrine Marchais-OberwinklerSMSandrine Marchais-Oberwinkler
- Martin FrotscherMFMartin Frotscher
- Tim PohlemannTPTim Pohlemann
- Michael D. MengerMMMichael D. Menger
- Rolf W. HartmannRHRolf W. Hartmann
- 15 January 2019
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 62 (3) , 1362-1372
Abstract
Current therapies of steroid hormone-dependent diseases predominantly alter steroid hormone concentrations (or their actions) in plasma, in target and nontarget tissues alike, rather than in target organs only. Targeted therapy through the inhibition of steroidogenic enzymes may pose an attractive alternative with much less side effects. Here, we describe the design of a nanomolar potent 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitor (compound 15) and successful targeted intracrine therapy in a mouse bone fracture model. Blockade of 17β-HSD2 in bone is thought to increase intracellular estradiol (E2) and testosterone (T), which thereby inhibits bone resorption by osteoclasts and stimulates bone formation by osteoblasts, respectively. Administration of compound 15 in the mouse fracture model strongly increases the mechanical stability of the healing fractured bone because of a larger periosteal callus with newly formed bone without changing the plasma E2 and T concentrations. Steroidogenic 17β-HSD2 inhibition thus enables targeted intracrine therapy.Keywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (031A467)
This publication has 27 references indexed in Scilit:
- An analysis of bone regeneration at a segmental bone defect by controlled release of bone morphogenetic protein 2 from a biodegradable sponge composed of gelatin and β-tricalcium phosphateJournal of Tissue Engineering and Regenerative Medicine, 2011
- Novel Hydroxysteroid (17β) Dehydrogenase 1 Inhibitors Reverse Estrogen-Induced Endometrial Hyperplasia in Transgenic MiceThe American Journal of Pathology, 2010
- Teriparatide for acceleration of fracture repair in humans: A prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fracturesJournal of Bone and Mineral Research, 2010
- Rescue of defective G protein–coupled receptor function in vivo by intermolecular cooperationProceedings of the National Academy of Sciences, 2010
- 11β-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in miceJournal of Experimental Medicine, 2005
- Purification, Reconstitution, and Steady-state Kinetics of the Trans-membrane 17β-Hydroxysteroid Dehydrogenase 2Journal of Biological Chemistry, 2002
- Activity and gene expression of 17β-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8The Journal of Steroid Biochemistry and Molecular Biology, 1998
- 17β-Hydroxysteroid Dehydrogenases in Human Bone CellsJournal of Bone and Mineral Research, 1998
- Estrogen synthesis by osteoblast cell linesEndocrinology, 1992
- 17β-Hydroxysteroid oxidoreductase: A ubiquitous enzyme. Interconversion of estrone and estradiol-17β in mouse tissuesMetabolism, 1985